13F-HR: Johnson & Johnson Discloses Q3 2024 Equity Holdings in SEC Form 13F Filing

Johnson & Johnson's latest 13F filing reveals a diverse portfolio of equity holdings totaling over $427 million as of September 30, 2024.

Summary

• Johnson & Johnson filed its Form 13F for the quarter ended September 30, 2024, disclosing its equity holdings.
• The total value of reported holdings is approximately $427.3 million.
• The filing includes 20 different equity positions.
• The largest holding by value is Protagonist Therapeutics Inc. at approximately $110.2 million.
• Other significant holdings include Rapport Therapeutics, Inc. at approximately $51.2 million and Legend Biotech Corporation at approximately $39.7 million.
• The filing also lists Johnson & Johnson Innovation JJDC, Inc. as another included manager.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of holdings, indicating a stable and active investment strategy. The sentiment is neutral to slightly positive due to the diversified portfolio and significant investments in promising companies.

Positives

• The filing demonstrates a diversified investment strategy across various biotechnology and healthcare companies.
• The large investment in Protagonist Therapeutics Inc. suggests a strong belief in the company's potential.
• The portfolio includes several companies in the biotech and pharmaceutical sectors, aligning with Johnson & Johnson's core business.

Negatives

• The filing does not provide details on the performance of these investments.
• The document does not provide any information on the reasons for the specific holdings.

Risks

• The value of these holdings is subject to market fluctuations and the performance of the individual companies.
• Investments in biotechnology and pharmaceutical companies carry inherent risks related to clinical trials, regulatory approvals, and market competition.

Industry Context

This filing reflects Johnson & Johnson's continued investment in the biotechnology and pharmaceutical sectors, which is consistent with their strategic focus on healthcare innovation.

Comparison to Industry Standards

• Johnson & Johnson's investment strategy, as reflected in this 13F filing, is comparable to other large pharmaceutical and healthcare companies that actively invest in emerging biotech firms.
• For example, similar filings from companies like Pfizer or Novartis would show a mix of investments in both established and early-stage companies in the healthcare space.
• The size of the portfolio, at $427 million, is within the range of what would be expected for a company of Johnson & Johnson's size and investment activity.
• The focus on companies like Protagonist Therapeutics, Rapport Therapeutics, and Legend Biotech aligns with the industry trend of investing in innovative therapies and technologies.

Stakeholder Impact

• The filing provides transparency to shareholders regarding Johnson & Johnson's investment activities.
• The investments in various biotech companies could potentially lead to future innovations and products that benefit patients and healthcare providers.

Key Dates

Keywords

Form 13F, Johnson & Johnson, Equity Holdings, Biotechnology, Pharmaceuticals, Investment Portfolio, Healthcare